KLRS vs ADMA vs GRFS vs REPL vs ALNY

For growth investors, Alnylam Pharmaceuticals, Inc.

(ALNY) is the stronger pick with 65. 2% revenue growth year-over-year, versus 0. 2% for Grifols, S. A. (GRFS). Grifols, S. A. (GRFS) offers the better valuation at 11. 6x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate ADMA Biologics, Inc. (ADMA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Grifols, S.

A. (GRFS) is the cheapest at 11. 6x versus Alnylam Pharmaceuticals, Inc. at 121. 4x. On forward P/E, Grifols, S. A. is actually cheaper at 8. 9x.

Over the past 5 years, ADMA Biologics, Inc.

(ADMA) delivered a total return of +346. 2%, compared to -74. 4% for Replimune Group, Inc. (REPL). Over 10 years, the gap is even starker: ALNY returned +366. 4% versus KLRS's -52. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alnylam Pharmaceuticals, Inc.

(ALNY) is the lower-risk stock at 0. 60β versus ADMA Biologics, Inc. 's 1. 11β — meaning ADMA is approximately 84% more volatile than ALNY relative to the S&P 500. On balance sheet safety, Kalaris Therapeutics Inc (KLRS) carries a lower debt/equity ratio of 2% versus 162% for Alnylam Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Alnylam Pharmaceuticals, Inc.

(ALNY) is pulling ahead at 65. 2% versus 0. 2% for Grifols, S. A. (GRFS). On earnings-per-share growth, the picture is similar: Alnylam Pharmaceuticals, Inc. grew EPS 206. 9% year-over-year, compared to -25. 9% for ADMA Biologics, Inc.. Over a 3-year CAGR, ALNY leads at 53. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ADMA Biologics, Inc.

(ADMA) is the more profitable company, earning 28. 8% net margin versus 0. 0% for Replimune Group, Inc. — meaning it keeps 28. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADMA leads at 37. 5% versus 0. 0% for REPL. At the gross margin level — before operating expenses — ALNY leads at 81. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Grifols, S.

A. (GRFS) trades at 8. 9x forward P/E versus 37. 7x for Alnylam Pharmaceuticals, Inc. — 28. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for KLRS: 331. 2% to $18. 67.

In this comparison, GRFS (2.

7% yield) pays a dividend. KLRS, ADMA, REPL, ALNY do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Alnylam Pharmaceuticals, Inc.

(ALNY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 60), +366. 4% 10Y return). Both have compounded well over 10 years (ALNY: +366. 4%, ADMA: +15. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: KLRS is a small-cap quality compounder stock; ADMA is a small-cap high-growth stock; GRFS is a small-cap deep-value stock; REPL is a small-cap quality compounder stock; ALNY is a mid-cap high-growth stock. GRFS pays a dividend while KLRS, ADMA, REPL, ALNY do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.